LifeVantage Corporation — Form 10-Q Summary
Reporting period: Second quarter and six months of fiscal 2024, ended December 31, 2023. The unaudited filing covers the quarter and six months compared with the corresponding 2022 periods. LifeVantage sells nutrition, wellness, personal-care and related products through independent consultants and customers in the Americas and Asia/Pacific & Europe.
Financial performance and liquidity
| Metric | Three months ended Dec. 31, 2023 | Prior-year quarter | Six months ended Dec. 31, 2023 | Prior-year six months |
|---|---|---|---|---|
| Net revenue | $51.6 million | $53.7 million | $103.0 million | $105.4 million |
| Gross profit / margin | $40.6 million / 78.6% | $41.9 million / 78.1% | $81.7 million / 79.4% | $83.7 million / 79.4% |
| Operating income (loss) | $(1.3) million | $(1.2) million | $(0.5) million | $0.1 million |
| Net income (loss) | $(0.7) million | $(1.1) million | $(0.03) million | $(0.4) million |
| Net loss per diluted share | $(0.05) | $(0.08) | $0.00 | $(0.04) |
- For the six months, operating cash flow was $6.5 million, versus cash used of $0.4 million a year earlier. Capital expenditures were $1.7 million.
- Cash declined $4.3 million from June 30 to $17.3 million. Financing used $9.2 million, including $6.0 million of dividends and $2.7 million of share repurchases.
- At December 31, working capital was $15.6 million, down from $24.7 million at June 30. Total assets were $62.7 million and stockholders’ equity was $27.3 million.
- No credit-facility balance was outstanding. Operating lease liabilities totaled $13.8 million. The company reported an 8.60% effective facility interest rate if drawn.
Material changes versus prior periods
- Quarterly revenue declined 3.8%; six-month revenue declined 2.3%. Americas revenue was down 1.6% for the quarter but up 2.0% for the six months. Asia/Pacific & Europe revenue fell 10.0% and 13.5%, respectively.
- Active accounts fell 12.1% year over year to 131,000, including 51,000 independent consultants (down 15.0%) and 80,000 customers (down 10.1%). Asia/Pacific & Europe active accounts declined 18.2%.
- TrueScience Liquid Collagen supported average revenue per account: related revenue was approximately $10.5 million for the quarter and $20.4 million for the six months. The company cited lower consultant/customer counts, China e-commerce closure, and foreign exchange as regional revenue headwinds.
- Commissions and incentives declined as a percentage of revenue, which management attributed partly to the Evolve Compensation Plan launched in March 2023 and lower promotional and incentive costs. SG&A rose as a percentage of revenue, partly due to proxy-contest expenses.
Outlook, risks and unusual items
- Management said cash and ongoing operating cash flow should be sufficient for requirements over at least the next 12 months. It gave no specific revenue or earnings guidance in the provided filing text.
- Management expects product launches to support revenue through higher average order size and customer and consultant attraction and retention, while noting that falling active accounts remain a concern. New products, market support and consultant retention are important business dependencies.
- The company breached its minimum fixed-charge-coverage covenant at December 31, 2023 and obtained a lender waiver. The facility was scheduled to mature March 31, 2024; the filing reports no outstanding borrowings. Other covenants restrict dividends, debt and other actions, and the facility is secured by substantially all assets.
- The company paid a one-time $0.40-per-share dividend in September 2023, in addition to quarterly dividends. It also repurchased 0.4 million shares for $2.7 million in the six-month period. The repurchase authorization had $24.2 million remaining at December 31.
- A stockholder rights plan adopted in August 2023 generally becomes exercisable if a person acquires 12% of the common stock (20% for passive investors); it was scheduled to expire August 24, 2024 unless earlier terminated, redeemed or exchanged.
- Management reported no probable loss contingencies requiring accrual or disclosure and did not expect other identified legal matters to have a material adverse effect, while acknowledging outcomes and related publicity could affect results. Disclosure controls were assessed as effective, with no material change in internal controls reported.
Important facts for investors to verify
- Whether the covenant waiver was followed by an amendment, renewed waiver, refinancing or repayment before the March 31, 2024 facility maturity.
- Whether operating cash flow remains sufficient given lower active accounts, declining regional revenue and the reduced working-capital balance.
- Whether the Evolve Compensation Plan and new products can stabilize consultant and customer counts and sustain revenue per account.
- The continuing cost and effect of the proxy contest, and the company’s subsequent dividend and repurchase decisions under facility restrictions.
- Developments in the rights plan, litigation or regulatory matters, and the impact of foreign exchange and the China e-commerce closure.